Long-term comorbidity patterns in juvenile idiopathic arthritis
Authors' conclusion
JIA patients with long-standing disease frequently develop comorbidities, particularly hypertension. Biologic therapy seems to reduce the risk of comorbidities.
Study context
- Population
- Adults with juvenile idiopathic arthritis (JIA) (2001 ILAR criteria) enrolled in the Portuguese Rheumatic Diseases Register (Reuma.pt)65.6% female
- Participants
- 748 adults
- Outcome
- Prevalence and incidence of key comorbidities
Methodological detailsnational, multicentre, register-based (Reuma.pt), Median age 27.7 years; median disease duration 20.6 years; oligoarticular JIA most common subtype (29.9%)
- National
- Multicentre
- Register-based (Reuma.pt)
- Median age 27.7 years; median disease duration 20.6 years; oligoarticular JIA most common subtype (29.9%)
Main finding
As reported in the abstract
Comorbidity incidence (per 1,000 person-years) and prevalence
- Incidence, autoimmune diseases (highest)
- 7.1/1,000 person-years
- Incidence, hypertension
- 5.1/1,000 person-years
- Incidence, psychiatric disease
- 4.0/1,000 person-years
- Prevalence, hypertension
- 9%
- Prevalence, psychiatric disease
- 8%
- Prevalence, osteoporosis
- 5%
Observational data: associations, not effects.
Further findings
| Outcome | OR | P value |
|---|---|---|
| Psychiatric disease, association with biologic DMARD useReduced risk | 0.38 | P = 0.03 |
Malignancy or infection, association with biologic DMARD use
- No significant association with malignancy or infection
Original publication
Long-term comorbidity patterns in juvenile idiopathic arthritis. Clin Exp Rheumatol. Published 23 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →